ArticleScientific reports2021
The transcriptome of Balamuthia mandrillaris trophozoites for structure-guided drug design.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Drug susceptibility of a clinical isolate ofAntimicrobial agents and chemotherapy · 2026Article
- Article
- Next-Generation Sequencing for Diagnosis of Fatal Balamuthia Amoebic Encephalitis: A Case Report.Diagnostics (Basel, Switzerland) · 2025Article
- Cyclic Peptide Natural Product Inspired Inhibitors of the Free-Living AmoebaJournal of natural products · 2025Article
- Understanding the pathogenicity of Naegleria fowleri in association with N. fowleri antigen-1 (Nfa1).Parasites, hosts and diseases · 2024Review
- Immunogens in Balamuthia mandrillaris: a proteomic exploration.Parasitology research · 2024Article
- Glucose metabolism in the pathogenic free-living amoebae: Tempting targets for treatment development.Chemical biology & drug design · 2024Review
- De Novo Transcriptome Profiling ofPathogens (Basel, Switzerland) · 2023Article
- Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes.Frontiers in microbiology · 2023Article
- Phenotypic assay for cytotoxicity assessment ofFrontiers in microbiology · 2023Article
- Distribution and Current State of Molecular Genetic Characterization in Pathogenic Free-Living Amoebae.Pathogens (Basel, Switzerland) · 2022Review
- Characterization of Glucokinases from Pathogenic Free-Living Amoebae.Antimicrobial agents and chemotherapy · 2022Article
- Application of the omics sciences to the study of Naegleria fowleri, Acanthamoeba spp., and Balamuthia mandrillaris: current status and future projections.Parasite (Paris, France) · 2021Review
- Challenges and advances in the medical treatment of granulomatous amebic encephalitis.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Balamuthia mandrillaris, a pathogenic free-living amoeba, causes cutaneous skin lesions as well as granulomatous amoebic encephalitis, a 'brain-eating' disease. As with the other known pathogenic free-living amoebas (Naegleria fowleri and Acanthamoeba species), drug discovery efforts to combat Balamuthia infections of the central nervous system are sparse; few targets have been validated or characterized at the molecular level, and little is known about the biochemical pathways necessary for parasite survival. Current treatments of encephalitis due to B. mandrillaris lack efficacy, leading to case fatality rates above 90%. Using our recently published methodology to discover potential drugs against pathogenic amoebas, we screened a collection of 85 compounds with known antiparasitic activity and identified 59 compounds that impacted the growth of Balamuthia trophozoites at concentrations below 220 µM. Since there is no fully annotated genome or proteome of B. mandrillaris, we sequenced and assembled its transcriptome from a high-throughput RNA-sequencing (RNA-Seq) experiment and located the coding sequences of the genes potentially targeted by the growth inhibitors from our compound screens. We determined the sequence of 17 of these target genes and obtained expression clones for 15 that we validated by direct sequencing. These will be used in the future in combination with the identified hits in structure guided drug discovery campaigns to develop new approaches for the treatment of Balamuthia infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.